Claims for Patent: 8,188,113

Summary for Patent: 8,188,113

Title:	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Abstract:	The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
Inventor(s):	Flynn; Daniel L. (Lawrence, KS), Petillo; Peter A. (Lawrence, KS), Kaufman; Michael D. (Lawrence, KS), Patt; William C. (Lawrence, KS)
Assignee:	Deciphera Pharmaceuticals, Inc. (Lawrence, KS)
Application Number:	11/854,354
Patent Claims:	1. A compound, or a salt thereof, of the formula IIa: ##STR00102## wherein Q1 is N and Q2 is CR3; wherein E1 is phenyl; wherein A is selected from the group consisting of phenyl, naphthyl, C3-C8carbocyclyl, --CHR4R8, pyridinyl, and benzothienyl; when A has one or more substitutable sp2-hybridized carbon atom, each respective sp2 hybridized carbon atom may be optionally substituted with a Z3 substituent; when A has one or more substitutable sp3-hybridized carbon atom, each respective sp3 hybridized carbon atom may be optionally substituted with a R3 substituent; each Z3 is independently and individually selected from the group consisting of H, methyl, ethyl, isopropyl, C3-C4 carbocyclyl, halogen, fluoroalkyl wherein the alkyl moiety can be partially or fully fluorinated, and cyano Z6 is (R3).sub.2N--; wherein each R3 is independently and individually selected from the group consisting of H, C1-C6alkyl, branched C3-C7alkyl, and C3-C8carbocyclyl; each R4 is independently and individually selected from the group consisting of C1-C4alkyl, branched C3-C5alkyl, and C3-C5carbocyclyl; each R8 is independently and individually selected from the group consisting of C3-C8carbocyclyl, and Z3-substituted phenyl; R16 is independently and individually selected from the group consisting of hydrogen, methyl, ethyl, halogen, fluoroalkyl wherein the alkyl moiety can be partially or fully fluorinated, cyano, and C2-C3alkynyl; and t is 1-3. 2. A compound of claim 1 having the formula IIb: ##STR00103## 3. A compound of claim 2 having formula IIv: ##STR00104## wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen, and wherein the substituent Z3 can be in either of the fused phenyl rings comprising the naphthyl ring. 4. A compound of claim 3 having formula IIw: ##STR00105## 5. A compound of claim 3 having formula IIx: ##STR00106## and wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 6. A compound of claim 2 having formula IIy: ##STR00107## and wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 7. A compound of claim 6 having formula IIz: ##STR00108## 8. A compound of claim 6 having formula IIaa: ##STR00109## wherein R16 is methyl, cyano, -ethynyl, or halogen. 9. A compound of claim 2 having formula IIbb: ##STR00110## wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 10. A compound of claim 9 having formula IIcc: ##STR00111## 11. A compound of claim 9 having formula IIdd: ##STR00112## wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 12. A compound of claim 2 having formula IIee: ##STR00113## wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 13. A compound of claim 12 having formula IIff: ##STR00114## 14. A compound of claim 12 having formula IIgg: ##STR00115## wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 15. A compound of claim 2 having formula IIhh: ##STR00116## and wherein R16 is methyl, ethyl, cyano, -ethynyl, or halogen. 16. A compound of claim 15 having formula IIii: ##STR00117## 17. A compound of claim 15 having formula IIjj: ##STR00118## and wherein R16 is methyl, cyano, -ethynyl, or halogen. 18. A compound selected from the group consisting of 1-(2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridi- n-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-methyl-5-(1-methyl-7- -(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)phenyl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(5-(1-ethyl-7-(methylainino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2- -fluoro-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-- fluoro-4-methylphenyl)-3-(naphthalen-1-yl)urea, 1-(2-fluoro-5-(1-isopropyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyr- idin-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-cyclohexyl-3-(2-fluoro-5-(1-isopropyl-7-(methylamino)-2-oxo-1,2-dihydro- -1,6-naphthyridin-3-yl)phenyl)urea, 1-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2- fluorophenyl)-3-(naphthalen-1-yl)urea, 1-(2-fluoro-5-(1-isopropyl-7-(methyl am ino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)phenyl)-3-(2-flu oro-5-(trifluoromethyl)phenyl)urea, 1-(4-chloro-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin- -3-yl)-2-fluorophenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(5-(1-ethyl-7-(methylamino)-2-ox- o-1,2-dihydro-1,6-naphthyridin-3-y1)-2-fluorophenyl)urea, 1-(4-chloro-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin- -3-yl)-2-fluorophenyl)-3-phenylurea, 1 (4-chloro-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- -yl)-2-fluorophenyl)-3-(2,3-difluorophenyl)urea, 1-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-- fluorophenyl)-3-(3-(trifluoromethyl)phenyl)urea, 1-(2-fluoro-5-(1-isopropyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyr- idin-3-yl)phenyl)-3-phenylurea, 1-(4-chloro-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin- -3-yl)-2-fluorophenyl)-3-(naphthalen-1-yl)urea, 1-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-- fluorophenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-cyclohexylurea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-phenylurea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(naphthalen-1-yl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(3-cyanophenyl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(2,3-difluorophenyl)urea, 1-(4-chloro-3-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin- -3-yl)phenyl)-3-cyclohexylurea, 1-cyclopropyl-3-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-- dihydro-1,6-naphthyridin-3-yl)phenyl)urea, (R)-1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,- 6-naphthyridin-3-yl)phenyl)-3-(1-phenylethyl)urea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(4-methyl-5-(trifluoromethyppyridin-3-yl)urea, 1-(2,4-difluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthy- ridin-3-yl)phenyl)-3-(5-(trifluoromethyppyridin-3-yl)urea, 1-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-- fluorophenyl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(4-fluoro-5-(trifluoromethyppyridin-3-yl)urea, 1-(4-chloro-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea, 1-(5-(7-amino-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoro-- 4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)ureal -(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-nap- hthyridin-3-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, 1-cyclohexyl-3-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyr- idin-3-yl)-2-fluoro-4-methylphenyl)urea,-1-cyclohexyl-3-(2-fluoro-5-(1-iso- propyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylph- enyl)urea,-1-cyclohexyl-3-(5-(1-cyclopentyl-7-(rnethylamino)-2-oxo-1,2-dih- ydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)urea, 1-cyclohexyl-3-(5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyr- idin-3-yl)-2-fluorophenyl)urea, 1-cyclohexyl-3-(2,4-difluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydr- o-1,6-naphthyridin-3-yl)phenyl)urea, 1-(4-cyano-2-fluoro-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-nap- hthyridin-3-yl)phenyl)-3-cyclohexylurea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-((1R,2R)-2-methylcyclohexyl)urea, 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-((1S,2S)-2-methylcyclohexyl)urea, and 1-(2-fluoro-4-methyl-5-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-na- phthyridin-3-yl)phenyl)-3-((1 r,4r)-4-methylcyclohexyl)urea. 19. A pharmaceutical composition comprising a compound of claims 1 or 18 and salts thereof, together with a pharmaceutically acceptable carrier, said carrier including an additive selected from the group including adjuvants, excipients, diluents, and stablilizers.